Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomas
Lin, W.-H.; Kosari, F.; Smadbeck, J. B.; Barrett, M. T.; Feathers, R. W.; Hall, J.; Sadeghian, D.; Sotiriou, S.; Johnson, S. H.; Harris, F. R.; Berry, T.; McCune, A. F.; Murphy, S. J.; Kinsella, L.; Haydu, L. E.; Moniz-Garcia, D.; Fortin Ensign, S. P.; Yang, L.; Emanuel, A. R.; Jones, L. A.; Schaefer-Klein, J. L.; Ida, C. M.; Salomao, M. A.; Sherman, W. J.; Porter, A. B.; Rosenfeld, S. S.; Kizilbash, S. H.; Jaeckle, K. A.; Mrugala, M. M.; Mansfield, A. S.; Borad, M. S.; Bendok, B. R.; Burns, T. C.; Quinones-Hinojosa, A.; Cheville, J. C.; Vasmatzis, G.; Anastasiadis, P. Z.
Show abstract
High-grade gliomas (HGGs) are aggressive tumors with poor outcomes and limited treatment options. Here, we combined genomic and transcriptomic tumor profiling with drug testing in a patient-derived 3-dimensional culture model to identify individualized treatments and predictive biomarkers. Activity of single agents targeting frequently dysregulated glioma pathways was relatively poor ex vivo and generally reflected historical patient data. However, compounds targeting PI3K, epigenetic, and survival/senescence signaling were effective in some cases. Drug sensitivity correlated with transcriptional rather than genomic features and suggested heterogeneity as a resistance mechanism. Bromodomain and extraterminal domain inhibition was particularly effective in tumors enriched in the mesenchymal transcriptional subtype, promoted proneural transition, and was overcome by upregulated PI3K signaling. Notably, combinations were largely effective, with 6 strategies exhibiting stronger efficacy than corresponding single agents in most cases (58-77%). This study identifies HGG vulnerabilities and associated biomarkers, resistance mechanisms, and effective combination strategies that warrant further clinical validation. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=171 SRC="FIGDIR/small/701806v1_ufig1.gif" ALT="Figure 1"> View larger version (31K): org.highwire.dtl.DTLVardef@cdb75corg.highwire.dtl.DTLVardef@1c133e6org.highwire.dtl.DTLVardef@1365153org.highwire.dtl.DTLVardef@11543a4_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 6 journals account for 50% of the predicted probability mass.